Physician profile
Mark Broering
NPI 1467714824
$9,408.53
in general payments reported to CMS, 2019-2025
24 companies · $692 in 2025
The $692 reported for 2025 was less than what a typical Vascular Surgery provider received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,447 · 2020: $1,707 · 2021: $1,547 · 2022: $1,296 · 2023: $593 · 2024: $1,128 · 2025: $692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,217 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,217.31 |
| Education | $194.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $3,208.73 | 2019-2025 | Gore Viabahn Vbx Balloon Expandable Endo, Gore Tag Conformable Thoracic Endoprosthesis, Excluder Conformable Aaa Endoprosthesis With Active Control |
| Bolton Medical INC | $1,709.65 | 2019-2022 | |
| Abbott Laboratories | $1,469.67 | 2019-2025 | Esprit, Jeti |
| Penumbra, INC. | $685.08 | 2019-2020 | |
| Inari Medical, INC. | $564.95 | 2019-2020 | |
| Shockwave Medical, INC | $320.33 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boston Scientific Corporation | $252.09 | 2019-2025 | Enhance Transcarotid Peripheral Access Kit |
| Medtronic, INC. | $204.09 | 2021-2024 | Heli-Fx Endoanchor System |
| Silk Road Medical, INC. | $188.48 | 2019-2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Cardiovascular Systems INC. | $145.43 | 2019-2021 | |
| Philips North America LLC | $141.56 | 2020 | |
| Angiodynamics, INC. | $136.12 | 2024 | Angiovac |
| Ethicon US, LLC | $101.75 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $53.19 | 2019 | |
| Pfizer INC. | $51.18 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.96 | 2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $25.87 | 2020-2021 | |
| Amarin Pharma, INC. | $21.47 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.21 | 2023 | |
| Daiichi Sankyo INC. | $20.18 | 2025 | Injectafer |
| Merck Sharp & Dohme LLC | $13.45 | 2019 | |
| Astellas Pharma US INC | $13.37 | 2022 | |
| Acell, INC. | $13.12 | 2019 | |
| Allergan, INC. | $12.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Broering listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.